Home / CYDY : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CYDY make money? Does CYDY have pricing power? What's the Earnings Whisper? Will CYDY profit more as the business scales? What is CYDY's management track record? Is CYDY's current price justified?

CytoDyn Inc.

$0.2 -$0.07 (-25.25%)

OTC · 15 Sep 2026 17:09 UTC

Previous Close

$0.2

Day Range

$0.2$0.21

Year Range

$0.18$0.4

Market Cap

276.55M

AVG Volume

1.76M

Trailing/Forward PE

-5.89/-

PEG ratio

-0.1

Dividend Yield

Next Earnings Date

2026-10-08

Primary Exchange

Other OTC

Revenue (USD) · TTM

CYDY Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q4	0
26 Q3	-5.92M
26 Q2	-5.92M
26 Q1	-5.92M
25 Q4	-5.92M
25 Q3	50K
25 Q2	50K
25 Q1	50K
24 Q4	50K
24 Q3	0

Net Income (USD) · TTM

CYDY Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q4	-42.7M
26 Q3	-38.79M
26 Q2	-38.86M
26 Q1	-21.02M
25 Q4	3.75M
25 Q3	-7.09M
25 Q2	-14.25M
25 Q1	-19.04M
24 Q4	-49.84M
24 Q3	-51.69M

Operating Income (USD) · TTM

CYDY Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q4	-22.43M
26 Q3	-21.04M
26 Q2	-18.74M
26 Q1	-17.34M
25 Q4	9.66M
25 Q3	8.09M
25 Q2	8.68M
25 Q1	8.99M
24 Q4	-18.06M
24 Q3	-15.2M

EBITDA (USD) · TTM

CYDY EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q4	-39.55M
26 Q3	-38.03M
26 Q2	-35.24M
26 Q1	-16.77M
25 Q4	8.61M
25 Q3	-1.97M
25 Q2	-7.73M
25 Q1	-10.69M
24 Q4	-39.91M
24 Q3	-41.45M

Cash Flows (USD) · TTM

CYDY Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q4	-17.25M
26 Q3	-17.98M
26 Q2	-17.42M
26 Q1	-16.66M
25 Q4	-8.77M
25 Q3	-4.75M
25 Q2	-2.13M
25 Q1	-1.05M
24 Q4	-10.98M
24 Q3	-12.74M

EPS (USD) · TTM

CYDY EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q4	-0.03
26 Q3	-0.03
26 Q2	-0.03
26 Q1	-0.02
25 Q4	0
25 Q3	-0.01
25 Q2	-0.02
25 Q1	-0.02
24 Q4	-0.05
24 Q3	-0.05

Expenses (USD) · TTM

CYDY Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q4	23.14M
26 Q3	21.43M
26 Q2	19.12M
26 Q1	17.73M
25 Q4	-9.66M
25 Q3	-8.11M
25 Q2	-8.7M
25 Q1	-9.02M
24 Q4	18.03M
24 Q3	15.17M

Shares Outstanding (USD) · TTM

CYDY Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q4	-1.63M
26 Q3	-1.41M
26 Q2	-1.3M
26 Q1	-1.66M
25 Q4	-1.61M
25 Q3	-1.48M
25 Q2	-2.01M
25 Q1	-2.05M
24 Q4	-2.42M
24 Q3	-2.66M

Employee Count

CYDY Employee Count by quarter
Period	Employee Count
2026	14
2025	13
2024	9
2023	12
2022	23
2021	24
2020	19
2019	16
2018	6
2017	6

PE Ratio

CYDY PE Ratio by quarter
Period	PE Ratio
Oct 25	86.73
Sep 25	88.26
Sep 25	97.4
Sep 25	95.35
Sep 25	105.55
Aug 25	100.03
Aug 25	99.07
Aug 25	91.73
Aug 25	85.9
Aug 25	97.6
Jul 25	98.92

Free Cash Flow Yield

CYDY Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-6.35%
Sep 26	-6.36%
Sep 26	-6.3%
Aug 26	-6.16%
Aug 26	-6.86%
Aug 26	-7.44%
Aug 26	-7.56%
Jul 26	-7.42%
Jul 26	-7.12%
Jul 26	-6.65%
Jul 26	-6.03%
Jul 26	-5.88%
Jun 26	-5.76%
Jun 26	-5.24%
Jun 26	-4.95%
Jun 26	-4.82%
May 26	-4.65%
May 26	-4.18%
May 26	-4.08%
May 26	-4.27%
May 26	-4.59%
Apr 26	-4.72%
Apr 26	-3.79%
Apr 26	-4.8%
Apr 26	-5.18%
Mar 26	-5.24%
Mar 26	-5.02%
Mar 26	-5.3%
Mar 26	-5.98%
Feb 26	-5.53%
Feb 26	-5.33%
Feb 26	-5.7%
Feb 26	-5.55%
Jan 26	-5.65%
Jan 26	-5.47%
Jan 26	-5.35%
Jan 26	-5.12%
Jan 26	-4.92%
Dec 25	-4.75%
Dec 25	-4.68%
Dec 25	-4.12%
Dec 25	-4.16%
Nov 25	-4.05%
Nov 25	-4.36%
Nov 25	-5.02%
Nov 25	-5.43%
Oct 25	-5.63%
Oct 25	-5.12%
Oct 25	-4.98%
Oct 25	-5.11%
Oct 25	-2.7%
Sep 25	-2.65%
Sep 25	-2.4%
Sep 25	-2.45%
Sep 25	-2.22%
Aug 25	-2.34%
Aug 25	-2.36%
Aug 25	-2.55%
Aug 25	-2.72%
Aug 25	-2.4%
Jul 25	-2.37%
Jul 25	-1.23%
Jul 25	-1.23%
Jul 25	-1.36%
Jun 25	-1.49%
Jun 25	-1.25%
Jun 25	-1.09%
Jun 25	-1.11%
May 25	-1.14%
May 25	-1.14%
May 25	-0.99%
May 25	-0.97%
May 25	-1.19%
Apr 25	-1.68%
Apr 25	-1.9%
Apr 25	-0.83%
Apr 25	-0.83%
Mar 25	-0.74%
Mar 25	-0.78%
Mar 25	-0.68%
Mar 25	-0.67%
Feb 25	-0.57%
Feb 25	-0.58%
Feb 25	-0.8%
Feb 25	-0.82%
Jan 25	-0.87%
Jan 25	-0.78%
Jan 25	-1.16%
Jan 25	-0.62%
Jan 25	-0.78%
Dec 24	-0.8%
Dec 24	-0.79%
Dec 24	-0.67%
Dec 24	-0.81%
Nov 24	-0.8%
Nov 24	-0.8%
Nov 24	-0.76%
Nov 24	-0.75%
Nov 24	-0.73%
Oct 24	-0.69%

Price to Sales

CYDY Price to Sales by quarter
Period	Price to Sales
Aug 26	-49.36
Aug 26	-44.32
Aug 26	-40.88
Aug 26	-40.2
Jul 26	-40.95
Jul 26	-42.67
Jul 26	-45.7
Jul 26	-50.44
Jul 26	-51.69
Jun 26	-52.81
Jun 26	-57.98
Jun 26	-61.43
Jun 26	-63.03
May 26	-65.31
May 26	-72.73
May 26	-74.43
May 26	-71.13
May 26	-66.15
Apr 26	-64.45
Apr 26	-80.18
Apr 26	-63.35
Apr 26	-56.79
Mar 26	-56.14
Mar 26	-58.69
Mar 26	-55.52
Mar 26	-49.24
Feb 26	-53.27
Feb 26	-55.28
Feb 26	-51.61
Feb 26	-53.08
Jan 26	-52.08
Jan 26	-53.81
Jan 26	-55.05
Jan 26	-57.55
Jan 26	-57.19
Dec 25	-59.28
Dec 25	-60.13
Dec 25	-68.3
Dec 25	-67.75
Nov 25	-69.5
Nov 25	-64.51
Nov 25	-56.11
Nov 25	-51.87
Oct 25	-49.97
Oct 25	-54.98
Oct 25	-56.49
Oct 25	-55.05
Oct 25	-54.9
Sep 25	-55.87
Sep 25	-61.66
Sep 25	-60.36
Sep 25	-66.82
Aug 25	-63.32
Aug 25	-62.71
Aug 25	-58.07
Aug 25	-54.38
Aug 25	-61.78
Jul 25	-62.62
Jul 25	7752.77
Jul 25	7738.03
Jul 25	7001.08
Jun 25	6386.95
Jun 25	7615.21
Jun 25	8681.33
Jun 25	8597.81
May 25	8325.14
May 25	8352.16
May 25	9573.05
May 25	9801.51
May 25	7981.23
Apr 25	5667.19
Apr 25	5011.3
Apr 25	5129.9
Apr 25	5154.33
Mar 25	5722.28
Mar 25	5471.89
Mar 25	6253.59
Mar 25	6326.88
Feb 25	7503.82
Feb 25	7301.56
Feb 25	5308.23
Feb 25	5227.61
Jan 25	4885.62
Jan 25	5447.47
Jan 25	3686.2
Jan 25	3382.43
Jan 25	2699.13
Dec 24	2612.87
Dec 24	2651.46
Dec 24	3132.72
Dec 24	2593.57
Nov 24	2606.06
Nov 24	2610.6
Nov 24	2751.34
Nov 24	2791.75
Nov 24	2883.01
Oct 24	3019.21
Oct 24	3371.08
Oct 24	3002.47
Oct 24	3098.48

EV/EBITDA

CYDY EV/EBITDA by quarter
Period	EV/EBITDA
Oct 25	39.52
Sep 25	40.19
Sep 25	44.17
Sep 25	43.28
Sep 25	47.71
Aug 25	45.31
Aug 25	44.89
Aug 25	41.7
Aug 25	39.17
Aug 25	44.25
Jul 25	44.83

Price to Book

CYDY Price to Book by quarter
Period	Price to Book
Dec 20	1081.76
Dec 20	1057.68
Dec 20	1002.48
Dec 20	630.19
Dec 20	467.63
Nov 20	533.86
Nov 20	511.78
Nov 20	497.73
Nov 20	509.77
Oct 20	498.73
Oct 20	493.72
Oct 20	563.96
Oct 20	656.28
Jul 17	18.37
Jul 17	20.17
Jun 17	19.68
Jun 17	18.37
Jun 17	16.8
Jun 17	16.54
Jun 17	15.22
May 17	15.75
May 17	13.91
May 17	13.65
May 17	14.7
Apr 17	15.22
Apr 17	14.7
Apr 17	18.11
Apr 17	15.18
Mar 17	15.69
Mar 17	16.19
Mar 17	16.7
Mar 17	16.19
Mar 17	17.2
Feb 17	18.47
Feb 17	18.97
Feb 17	19.23
Feb 17	17.96
Jan 17	17.96
Jan 17	18.72
Jan 17	19.4
Jan 17	15.01
Dec 16	14.58
Dec 16	15.12
Dec 16	15.32
Dec 16	15.44
Dec 16	15.86
Nov 16	14.36
Nov 16	14.68
Nov 16	14.53
Nov 16	14.25
Oct 16	14.81
Oct 16	14.36
Oct 16	13.92
Oct 16	8.42
Sep 16	8.41
Sep 16	8.54
Sep 16	9.19
Sep 16	11.32
Sep 16	12.33
Aug 16	12.8
Aug 16	13.28
Aug 16	12.69
Aug 16	12.09
Jul 16	12.21
Jul 16	12.21
Jul 16	9.82
Jul 16	10.29
Jul 16	10.38
Jun 16	10.95
Jun 16	12.72
Jun 16	11.32
Jun 16	10.57
May 16	8.98
May 16	9.34
May 16	9.82
May 16	10.85
Apr 16	11.13
Apr 16	11.74
Apr 16	11.04

No video analysis for this stock yet. Request one from our team.

News: CYDY

globenewswire.com · 15 Sep 2026

CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th

VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E.

globenewswire.com · 1 Sep 2026

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $16.5 million in gross proceeds, with Paulson Investment Company acting as placement agent.

prnewswire.com · 22 Jul 2026

Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock

TACOMA, Wash., July 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP announces proposed class action settlement on behalf of purchasers of CytoDyn Inc. common stock between March 27, 2020 and March 30, 2022 (OTCQB: CYDY): UNITED STATES DISTRICT COURTWESTERN DISTRICT OF WASHINGTON AT TACOMA BRIAN JOE COURTER, COURTER AND SONS LLC, DIANE M.